T. Rowe Price Associates

Tracked participation in 2 Atlas companies, with 0 explicitly attributed leads.

2portfolio companies

3round participations

0lead positions

Sep 2023latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:Biomedicines—Nov 2021 → Sep 20232 roundsParticipant—

GTGenesis Therapeutics—Dec 2020 → Dec 20201 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Sep 14, 2023GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:BiomedicinesSeries C$273M—Participant

Source ↗

Nov 18, 2021GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:BiomedicinesSeries B$370M—Participant

Source ↗

Dec 02, 2020GTGenesis TherapeuticsSeries A$52M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗

Dec 02, 2020GTGenesis TherapeuticsSeries A$52M—Participant

Source ↗